Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II cardiac safety trial of liposomal pegylated doxorubicin in NED breast cancer after prior anthracyclines
2006-000251-18Phase 2Active
- Sponsor
- Dr. Llombart Cussac
- Start
- Mar 2006
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin in breast cancer, sponsored by Dr. Llombart Cussac. Primary endpoint: Cardiotoxicity rate. Started Mar 2006; status: active.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-000251-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000251-18.